Field Trip Health Ltd.

Greetings. Welcome to Field Trip Health Year-End 2021 Earnings Conference Call. At this time, all participants are in listen-only mode. A brief question and answer session will follow the formal presentation. If anyone should require operator assistance during the conference, please press star zero from your telephone keypad. Please note this conference is being recorded. At this time, we'll now turn the conference over to Elizabeth Barker, Senior Vice President, Investor Relations. Elizabeth, you may now begin.

Thank you. Welcome everyone to Fieldtrip's fiscal year-end March 2021 financial results conference call. Before I begin the call, I'm obligated to remind everyone that during the course of this conference call, management may be making some forward-looking statements that are based on current expectations and are subject to a number of risks and uncertainties that may cause actual results to differ materially from expectations. These results are outlined in the risk factors section of our filings and our disclosure materials. Any forward-looking statements should be considered in light of these factors. Please also note, as Safe Harbor, any outlook we present is as of today, and management does not undertake any obligations to revise any forward-looking statements in the future. With that out of the way, let me quickly introduce the management team. On the phone with us, we have Ronan Levy, co-founder and executive chairman, Joseph Del Moral, co-founder and CEO, Donna Wong, CFO, and Dr. Nathan Bryson, chief scientific officer. I'll now turn the call over to Ronan to provide some insights into the company's strategic direction.

Thank you, Elizabeth, and welcome everyone who has joined us for our fiscal year 2021 earnings call. Fiscal 2021 was truly a momentous year for Fieldtrip. Through the execution of our business plan over the past year, we've emerged as one of the foremost players in the psychedelic sector. In a relatively short space of time, we have built out an integrated business focused on the end-to-end development and delivery of psychedelic therapies. This has propelled us into a leadership position in the industry. And as a result, we are receiving significant support as the value of our work is increasingly recognized by other industry players and leading financial institutions. We have attracted world-class scientists. a first-class development team and expert psychotherapist who are all working together to explore the huge potential benefits and wide applications of psychedelics and psychedelic-enhanced therapies. In recent weeks, former U.S. Senate Majority Leader and preeminent expert on health policy reform, Tom Daschle, joined us as a special advisor to Fieldtrip. We are looking forward to working with Senator Daschle to advance society's understanding of psychedelics, and their potential to revolutionize our approach to mental, emotional, and behavioral health. We also crucially have received support from the investment community, including raising $115 million in two bought deal offerings in January and March. Our March bought deal offering was led by Solius Capital with additional participation from Avidity Partners, Sphera Funds, Pura Vida Investments, Jenison Associates, and others. This support and endorsement provided from some of the world's leading healthcare specialized investors is a powerful validation of our strategy and achievements thus far. We keep our shareholders' best interest at the heart of our decisions. Earlier this month, we bolstered our board of directors with the appointment of Barry Fishman and Ellen Lubman. These appointments complement our existing independent board members, Dieter Winand and Helen Boudreaux, to establish a board powered by the highest caliber of accomplished pharmaceutical and biotech executives. We also successfully uplisted to the Toronto Stock Exchange and are working towards making our shares more accessible to the US investor base. We secured DTC eligibility last month and shortly after that filed an application to list on the NASDAQ. We believe that listing on NASDAQ will unlock various opportunities to enhance corporate visibility, increase liquidity, and broaden overall awareness of Fieldtrip to a larger investor base while driving value for our shareholders. The psychedelics industry stands poised to disrupt modern psychiatry, and we are positioned to leverage this phenomenal opportunity to build value for our shareholders. by executing quickly to continue to leverage our early-mover advantage in this industry that is expected to be worth more than $100 billion, according to some estimates. As the psychedelics industry gains more and more traction, interest in field trip continues to increase. In recent months, we have been invited to attend the Jefferies Healthcare Conference, the H.C. Wainwright Psychedelic and Psychiatry Conference, the Benchmark Company Healthcare Conference, the Bloom, Burton & Co. Healthcare Investor Conference in April, and the Canaccord Psych Conference, We've also been interviewed on CNBC and featured in Bloomberg, as well as making the front page of the New York Times this past month. This is a testament to the strides we have made building Fieldtrip into nothing less than a world-class leader in the mental and behavioral health sectors through our pioneering work with psychedelics and psychedelic therapies. As a result of the groundwork laid last year, we expect to complete our preclinical studies by the end of this calendar year or early next year, expand our drug development pipeline, and leverage our clinic networks to further validate our positive clinical outcomes. With that, I'll turn the call over to Joseph Del Moral to discuss our recent operational achievements and to lay out our strategic objectives for fiscal 2022. Thank you, Ronan.